TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23173246

Group type: EXPERIMENTAL
Intervention: bushui roumu recipe (BRR) combined with medroxyprogesterone acetate tablet (MAT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: bushui roumu recipe (BRR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: artificial period method (Western medicine group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 20819495

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 97
Study: 17934163

Group type: EXPERIMENTAL
Intervention: Stimulating, three-hole catheter (S3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-stimulating three-hole catheter (NS3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stimulating, open-ended hole catheter (S1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All catheter types
Number of subjects: 60
Study: 15975301

Group type: EXPERIMENTAL
Intervention: Rebixiao granules (RBXG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Futalin tablets (diclofenac sodium)
Number of subjects: 90
Study: 12474115

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg, PO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (baseline sleep)
Number of subjects: 20
Study: 15512257

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound (TAS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (not released results)
Number of subjects: 130
Study: 7751433

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1969172

Group type: EXPERIMENTAL
Intervention: Bromazepam (3 mg, two daily doses)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Chlorprothixene (15 mg, two daily doses)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 351848

Group type: EXPERIMENTAL
Intervention: Active aerosol (betamethasone valerate, 800 microgram/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral prednisone or prednisolone (30 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 36
Study: 30715214

Group type: EXPERIMENTAL
Intervention: miR-1908-5p
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: miR-10b-5p
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Higher plasma level of miR-199a
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: miR-143-3p and miR-145-5p
Number of subjects: 710
Study: 27898343

Group type: EXPERIMENTAL
Intervention: Caregiver gaze condition
Number of subjects: 49

Group type: COMPARATOR
Intervention: Stranger gaze condition
Number of subjects: 49
Study: 26123789

Group type: EXPERIMENTAL
Intervention: Oral lipid tolerance test (OLTT)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Aerobic fitness level
Number of subjects: 214
Study: 24435725

Group type: COMPARATOR
Intervention: Standard restraints
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reversible pre-tensioned restraints
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal driving
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Steady state braking
Number of subjects: 20
Study: 21866656

Group type: EXPERIMENTAL
Intervention: Quyu Jiedu Recipe (QYJDR) after laparoscopic surgery for 12 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine progesterone treatment after laparoscopic surgery
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Quyu Jiedu Recipe (QYJDR) after laparoscopic surgery
Number of subjects: 130
Study: 19196362

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: General health perception
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Reported AEs
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Multiple drugs
Number of subjects: 680
Study: 16924049

Group type: EXPERIMENTAL
Intervention: Low-dose acitretin (25 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose acitretin (50 mg/d)
Number of subjects: 0
Study: 15054734

Group type: EXPERIMENTAL
Intervention: Vitamin E (VE) oil solution rinse before and after radiotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo oil solution rinse before and after radiotherapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vitamin E (VE) oil solution rinse
Number of subjects: 54
Study: 11532411

Group type: EXPERIMENTAL
Intervention: Master surgeons
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medical students
Number of subjects: 20
Study: 9263195

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saccharin (50 mg)
Number of subjects: 0
Study: 8198625

Group type: EXPERIMENTAL
Intervention: calcium (800 mg/day) + vitamin D3 placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: vitamin D3 (5 micrograms/day) + calcium placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: calcium + vitamin D3
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 58
Study: 3733916

Group type: EXPERIMENTAL
Intervention: Detached attitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Involved attitude
Number of subjects: 0
Study: 31391139

Group type: EXPERIMENTAL
Intervention: Institutionally-reared children
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Institutionalization
Number of subjects: 188

Group type: COMPARATOR
Intervention: Never-institutionalized children
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: EF assessment
Number of subjects: 188
Study: 30514434

Group type: EXPERIMENTAL
Intervention: Visual Schema Displacement Therapy (VSDT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: abbreviated EMDR protocol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 105
Study: 28403360

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) (Fuji ORTHO LC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Light cured composite resin (Transbond XT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Topical application of 1.23% acidulated phosphate fluoride (APF)
Number of subjects: 29
Study: 26177348

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA group)
Number of subjects: 72
Study: 23635560

Group type: EXPERIMENTAL
Intervention: Weekly administration of paclitaxel, carboplatin, and trastuzumab (12 doses over 16 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Every-3-weeks administration of paclitaxel, carboplatin, and trastuzumab (4 doses over 12 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Weekly administration in luminal-B (HER2-positive) tumors
Number of subjects: 56

Group type: COMPARATOR
Intervention: Every-3-weeks administration in luminal-B (HER2-positive) tumors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Weekly administration in ERBB2+ tumors
Number of subjects: 56

Group type: COMPARATOR
Intervention: Every-3-weeks administration in ERBB2+ tumors
Number of subjects: 56
Study: 21501803

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (educational institution-based peer education, teacher training, community peer education, health information materials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (in rural community)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (in urban community)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community peer education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Institution-based interventions
Number of subjects: 0
Study: 18505646

Group type: COMPARATOR
Intervention: Amalgam (negative control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hybrid resin composite (TPH, Dentsply) with prior acid conditioning and bonding with an etch-and-rinse adhesive (Prime&Bond NT, Dentsply)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite (Dyract, Dentsply) bonded with Prime&Bond NT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dyract with prior nonrinse conditioner (NRC) treatment and bonding with Prime&Bond NT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite (F2000) in conjunction with a self-etch adhesive (Prompt-L-Pop, 3M/ESPE)
Number of subjects: 75
Study: 17172172

Group type: EXPERIMENTAL
Intervention: Daily supplementation with a complex containing Ester-C with antioxidants (2100 mg of Ca-ascorbate + 340 mg of bioflavonoids)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15522042

Group type: EXPERIMENTAL
Intervention: Jumping mechanography
Number of subjects: 258

Group type: COMPARATOR
Intervention: Chair-rising test
Number of subjects: 258
Study: 11155094

Group type: EXPERIMENTAL
Intervention: Octreotide LAR (3 injections at 4 week intervals)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lanreotide (5 injections at 14 day intervals)
Number of subjects: 27
Study: 9125696

Group type: EXPERIMENTAL
Intervention: Bright Light-Caffeine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dim Light-Caffeine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Bright Light-Placebo
Number of subjects: 4

Group type: COMPARATOR
Intervention: Dim Light-Placebo
Number of subjects: 4
Study: 8103112

Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxisylyte
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intracavernous administration of moxisylyte
Number of subjects: 12
Study: 3756776

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide, vincristine, and prednisone [CVP], five courses)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Whole‐abdominal irradiation (25 Gy/20 Fr)
Number of subjects: 113
Study: 29390245

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Darboepoetin alfa
Number of subjects: 29

Group type: COMPARATOR
Intervention: Estorclean PLUS
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous iron therapy with sodium ferrigluconate
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Global savings with epoetin alfa
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Global savings with darboepoetin alfa
Number of subjects: 29
Study: 26903081

Group type: EXPERIMENTAL
Intervention: Mind-body program (8-week group program followed by 6 monthly sessions)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Mind-body program
Number of subjects: 282

Group type: COMPARATOR
Intervention: Health education program (control)
Number of subjects: 282
Study: 25487561

Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 16
Study: 23377510

Group type: EXPERIMENTAL
Intervention: Dapsone 5% gel
Number of subjects: 2898

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2898
Study: 23120716

Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Semont's manoeuvre
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Brandt‐Daroff exercises
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Any of the three manoeuvres
Number of subjects: 48
Study: 18525395

Group type: EXPERIMENTAL
Intervention: Oscillometric blood pressure devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 0
Study: 15593011

Group type: EXPERIMENTAL
Intervention: 2-dose IPT with SP
Number of subjects: 1163

Group type: COMPARATOR
Intervention: weekly CQ chemoprophylaxis
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: 2-dose IPT with CQ
Number of subjects: 1163
Study: 11834680

Group type: EXPERIMENTAL
Intervention: Prednisone, 60 mg/d for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11207478

Group type: EXPERIMENTAL
Intervention: Human albumin 5% (HA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gelatine 4% (GEL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch solution 6% (HES)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ringer's solution
Number of subjects: 60
Study: 9408699

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (750 mg twice a day for 3 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no anti-viral prophylaxis)
Number of subjects: 44
Study: 8487654

Group type: EXPERIMENTAL
Intervention: Heparin administration prior to FSIGT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline administration prior to FSIGT
Number of subjects: 0
Study: 3104750

Group type: EXPERIMENTAL
Intervention: TRH (thyrotropin-releasing hormone) at 10 mg per kg on alternate days for 3 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TRH (thyrotropin-releasing hormone)
Number of subjects: 12
Study: 30983412

Group type: EXPERIMENTAL
Intervention: TCTR (Thread Carpal Tunnel Release)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control hand
Number of subjects: 20
Study: 28470504

Group type: EXPERIMENTAL
Intervention: Food deprivation (short period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline (no food deprivation)
Number of subjects: 0
Study: 27717393

Group type: EXPERIMENTAL
Intervention: 9-month multicomponent intervention including ongoing support, provision of resources, performance monitoring and feedback, executive support and recognition.
Number of subjects: 53
Study: 24006239

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 22315336

Group type: EXPERIMENTAL
Intervention: Adjuvanted 3.75-μg HA/AS03(A)
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Adjuvanted formulation (2 doses) or 1 dose of adjuvanted 3.75-μg HA formulation
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 1340
Study: 20555305

Group type: EXPERIMENTAL
Intervention: Prophylactic valganciclovir
Number of subjects: 115

Group type: COMPARATOR
Intervention: Preemptive valganciclovir
Number of subjects: 115
Study: 18175736

Group type: EXPERIMENTAL
Intervention: High-protein, low-carbohydrate (LC) ketogenic diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-protein, medium-carbohydrate (MC) nonketogenic diet
Number of subjects: 17
Study: 16186072

Group type: EXPERIMENTAL
Intervention: Soy protein containing 99mg isoflavones (aglycone weights)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Milk protein (placebo)
Number of subjects: 202
Study: 14671904

Group type: EXPERIMENTAL
Intervention: Plapherone LB (sublingually, 2 mg protein/day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine intensive therapy
Number of subjects: 94
Study: 10804025

Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone 1-34 (hPTH(1-34)) daily injections for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone 1-34 (hPTH(1-34))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen-only group (control)
Number of subjects: 0
Study: 8956699

Group type: EXPERIMENTAL
Intervention: Serum CA 125 concentration > or = 30 U/ml
Number of subjects: 22000

Group type: EXPERIMENTAL
Intervention: Serum CA 125 concentration > 100 U/ml
Number of subjects: 22000

Group type: COMPARATOR
Intervention: Serum CA 125 concentration < 30 U/ml
Number of subjects: 22000

Group type: COMPARATOR
Intervention: Entire study population
Number of subjects: 22000
Study: 1658962

Group type: EXPERIMENTAL
Intervention: 1500 aPTT-U low-molecular-weight heparin plus 0.5 mg dihydroergotamine (Embolex)
Number of subjects: 110

Group type: COMPARATOR
Intervention: twice daily administration of 5000 IU of the heparin-dihydroergotamine combination (Heparin-Dihydergot)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Embolex
Number of subjects: 110

Group type: COMPARATOR
Intervention: Heparin-Dihydergot
Number of subjects: 110
Study: 30660687

Group type: EXPERIMENTAL
Intervention: Ultra-processed food consumption at preschool age
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 307
Study: 28537769

Group type: COMPARATOR
Intervention: KSR2-rs7973260 A allele
Number of subjects: 1788
Study: 25663083

Group type: EXPERIMENTAL
Intervention: Laser alone at 975nm (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Laser alone at 924/975nm simultaneously (group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Curettage alone (group 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Laser at 924/975nm followed by curettage (group 4)
Number of subjects: 100
Study: 23838709

Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anesthesia (group S)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (group T)
Number of subjects: 193
Study: 21092958

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 58

Group type: COMPARATOR
Intervention: COC
Number of subjects: 58
Study: 20041778

Group type: EXPERIMENTAL
Intervention: Red ginseng extract-containing herbal mixture at 3 g/day
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 17584667

Group type: COMPARATOR
Intervention: Normal group (healthy subjects)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ICD patients
Number of subjects: 20
Study: 15764166

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for 5 days, repeated 3 times with a 23-day interval
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 103
Study: 11774114

Group type: EXPERIMENTAL
Intervention: Bipedal bioelectrical impedance analysis (BIA)
Number of subjects: 0
Study: 10723506

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyurea + Didanosine (DDI)
Number of subjects: 0
Study: 7641514

Group type: EXPERIMENTAL
Intervention: Group physical therapy
Number of subjects: 67
Study: 2616205

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine-gum (8-12 gums a day for one month)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo-gum (8-12 gums a day for one month)
Number of subjects: 14
Study: 310339

Group type: EXPERIMENTAL
Intervention: Combined adjuvant immunotherapy (bacillus Calmette‐Guérin and levamisole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 0
Study: 31634401

Group type: EXPERIMENTAL
Intervention: Inhibitory continuous theta burst stimulation (cTBS) over right inferior parietal lobe (IPL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo over left inferior parietal lobe (IPL)
Number of subjects: 20
Study: 30587963

Group type: EXPERIMENTAL
Intervention: Irbesartan and hydrochlorothiazide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Irbesartan alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard treatment for AECOPD
Number of subjects: 80
Study: 28608582

Group type: EXPERIMENTAL
Intervention: Childhood leukaemia diagnosed at age 5‐15 years
Number of subjects: 1871

Group type: EXPERIMENTAL
Intervention: Acute lymphoid leukaemia (ALL) diagnosed at age 0‐4 years
Number of subjects: 1871

Group type: EXPERIMENTAL
Intervention: Overall childhood leukaemia
Number of subjects: 1871
Study: 25447602

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) infusion (0.2 to 0.4 mg/kg, administered over 10 to 15 minutes)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) infusion
Number of subjects: 14
Study: 22177936

Group type: EXPERIMENTAL
Intervention: HF‐rTMS (10 Hz rTMS to the lesional hemisphere)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LF‐rTMS (1 Hz rTMS to the nonlesional hemisphere)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 29
Study: 21315224

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (TP) group
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No Thrombocytopenia (non-TP) group
Number of subjects: 1000
Study: 19236695

Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation assay (LPA) to ESAT-6
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation assay (LPA) to Ag85
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation assay (LPA) to Mycobacterium tuberculosis whole cell lysate (WCL)
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST)
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: ESAT-6 LPA
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Ag85 LPA
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: WCL LPA
Number of subjects: 1885
Study: 16702898

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 948
Study: 15110926

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (women without PMDD)
Number of subjects: 24
Study: 10778252

Group type: EXPERIMENTAL
Intervention: Patient groups (95 women)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (96 women)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 199
Study: 9264500

Group type: EXPERIMENTAL
Intervention: Perindoprilat (5 nmol/mL)
Number of subjects: 8
Study: 8405850

Group type: EXPERIMENTAL
Intervention: Liquid yeast sucrase
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3093468

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 83
Study: 31877310

Group type: EXPERIMENTAL
Intervention: Instant removal of colorectal polyps during the insertion phase
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (polyp removal during withdrawal phase)
Number of subjects: 220
Study: 29405819

Group type: EXPERIMENTAL
Intervention: Rebound therapy exercise (10-30 minutes, three sessions a week for 12 weeks)
Number of subjects: 16
Study: 27613125

Group type: EXPERIMENTAL
Intervention: Head-mounted display-assisted teaching
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Head-mounted display self-learning
Number of subjects: 14